Xintian Pharma(SZ:002873) Bei Ke Cai Jing·2025-10-21 11:44Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. announced a share reduction plan by its controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., aiming to sell up to 7,050,000 shares, representing 2.9962% of the total share capital after excluding shares in the repurchase account, between November 11, 2025, and February 10, 2026 [1][2]. Group 1: Shareholder Actions - As of now, Shanghai Xintian Zhiyao holds 75,485,566 shares of Xintian Pharmaceutical, accounting for 32.0809% of the total share capital after excluding repurchased shares [2]. - If the maximum reduction is executed, it is estimated that Shanghai Xintian Zhiyao will cash out approximately 75.72 million yuan based on the closing price of 10.74 yuan per share on October 21 [2]. - The planned reduction is intended to reduce the equity pledge risk and enhance the stability of the company's shares [3]. Group 2: Financial Performance - Xintian Pharmaceutical has experienced a continuous decline in performance, with projected revenues of 954 million yuan and 858 million yuan for 2023 and 2024, respectively, reflecting year-on-year declines of 12.29% and 10.11% [6]. - The net profit attributable to the parent company is expected to be 80.87 million yuan and 52.32 million yuan for 2023 and 2024, showing year-on-year declines of 27.48% and 35.30% [6]. - In the first half of 2025, the company reported a net profit of only 576,600 yuan, marking the lowest level for the same period since its listing, with a revenue drop of 18.88% [6]. Group 3: Cost and Compliance Issues - The company has faced rising costs due to the continuous increase in raw material prices, impacting its main products, alongside fluctuations in the clinical market due to industry policy changes [6]. - Xintian Pharmaceutical has been implicated in bribery allegations, with reports suggesting improper conduct involving over 100 doctors across 37 medical institutions in Sichuan [7]. - Despite a decrease in sales expenses over the past two years, the sales expense ratio has consistently remained above 40%, with figures of 532 million yuan, 438 million yuan, 372 million yuan, and 159 million yuan for the years 2022 to the first half of 2025, respectively [7].